In conclusion, circPLXNB2 was highly expressed in AML patients and cells and modulated tumor progression by regulating the circPLXNB2/miR-654-3p/CCND1 axis, suggested that circPLXNB2 might be a new therapeutic target for AML treatment.
CircPLXNB2 regulates acute myeloid leukemia progression through miR-654-3p/CCND1 axis.